The Food and Drug Administration on Friday, May 24, gave final approval to Novartis’ spinal muscular atrophy treatment, Zolgensma, MM&M reports. The drug will cost $2.1 million.
Novartis, according to the report, says the health benefits gained from the gene therapy justify the $2.1 million price tag.
“The approval of Zolgensma is a testament to the transformational impact gene therapies can have in reimagining the treatment of life-threatening genetic diseases like spinal muscular atrophy,” Novartis CEO Vas Narasimhan said in a statement. “We believe Zolgensma could create a lifetime of possibilities for the children and families impacted by this devastating condition.”
To read more on MM&M, click here.